Anika Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
01/11/2024 03:48
* Anika Therapeutics Inc ANIK.OQ reported a quarterly
adjusted
loss of 25 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -45 cents. The mean expectation of two analysts
for the quarter was for a loss of one cent per share. Wall
Street expected results to range from -9 cents to 6 cents per
share.
* Revenue fell 6.5% to $38.75 million from a year ago;
analysts
expected $42.08 million.
* Anika Therapeutics Inc's reported EPS for the quarter was
a loss
of $2.03.
* The company reported a quarterly loss of $29.92 million.
* Anika Therapeutics Inc shares had fallen by 0.1% this
quarter and gained 8.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 137.5% in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "strong buy"
Wall Street's median 12-month price target for Anika
Therapeutics Inc is $32.50
This summary was machine generated from LSEG data November 1 at
03:48 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.01 -0.25 Missed
Jun. 30 2024 0.05 -0.01 Missed
Mar. 31 2024 -0.19 -0.31 Missed
Dec. 31 2023 -0.26 -4.30 Missed